CHAPEL HILL, N.C., Dec. 18 /PRNewswire/ -- Despite all the scientific advancements in drug discovery and development, it's still a long and expensive trip from the lab to the marketplace. To make that investment of time and money pay off, best-in-class pharmaceutical companies have learned to inject commercial insights early in the product development process, according to research from Best Practices, LLC.
"It's clear early integration of commercialization activities pays off, be it eliminating an unpromising compound early in the development process or achieving success at product launch," said Chris Bogan, chief executive officer of Best Practices, LLC.
The 113-page study found that organizational form or structure is a critical enabler of early integration of commercial activities. Leading companies build an organizational structure that fosters commercialization excellence through integrated portfolio, project and process management programs across a compound's development cycles, according to the study.
The report, "From Genes to Giants: Best Practices in Early-Stage Commercialization," will help leaders in new product planning and market research learn best practices in early-stage product commercialization. The study contains a wealth of insights gleaned from interviews and benchmark surveys with pharma companies such as Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Novartis, and Pfizer.
To download a complimentary summary of the study, go to
Some of the findings to emerge from the study include:
-- Centralize early and late-stage commercialization functions to
cultivate better integration among people, resources, activities and
-- Employ integrated tools, techniques and tactics for portfolio
management and decisi
|SOURCE Best Practices, LLC|
Copyright©2007 PR Newswire.
All rights reserved